A study of trontinemab for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to complete study procedures like brain scans and memory tests with a study partner's help.
- You have early Alzheimer's disease, either mild cognitive impairment or mild dementia, confirmed by a brain scan or spinal fluid test.
- You have a study partner who can come to visits and report on your daily life.
- Your memory test score must be at least 22 on the MMSE (a common memory screening) and your overall function must be mildly impaired.
- You do not have other conditions like a recent stroke, brain injury, tumor, or unstable medical illness that could affect thinking.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.